H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth

Tempus AI, Inc. (NASDAQ: TEM ) ranks among the best short squeeze stocks to invest in . Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, up 36.1% year-over-year and above H.C. Wainwright’s expectation of $345.3 million.

On the other hand, the company reported a net loss of $125.9 million, or $0.71 per diluted share, which was greater than H.C. Wainwright’s expected loss of $84.7 million. The firm stated that the operating loss has increased in comparison to previous quarters.

Tempus AI, Inc. (NASDAQ:TEM) expanded a number of partnerships during the quarter, including its collaboration with Gilead to offer enterprise-wide accessibility to its AI-driven Lens platform and a multi-year strategic partnership with Merck to expedite biomarker discovery and development. In addition, the company revealed results from the ALERT trial with Medtronic, which showed that its AI-driven EHR alerts improved life-saving heart valve operations by 40%.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years